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IgA nephropathy (IgAN) is characterized by deposits of IgA in
the renal mesangium. It is thought that deposits of IgA
mainly involve high molecular weight (HMW) IgA1. However,
there is limited information on the exact composition of
HMW IgA in these deposits. In this study, we investigated the
presence of secretory IgA (SIgA) in human serum and in the
glomerular deposits of a patient with IgAN. Furthermore, we
analyzed the interaction of SIgA with mesangial cells. With
enzyme-linked immunosorbent assay, SIgA concentrations in
the serum of IgAN patients and healthy controls were
measured. Both patients and controls had circulating SIgA
that was restricted to the HMW fractions. Patients tended to
have higher levels of SIgA, but this difference was not
significant. However, in patients with IgAN, high serum SIgA
concentrations were associated with hematuria. Binding of
size-fractionated purified serum IgA and SIgA to mesangial
cells was investigated with flow cytometry. These studies
showed stronger binding of SIgA to primary mesangial cells
compared to binding of serum IgA. Importantly, after
isolation and elution of glomeruli from a nephrectomized
transplanted kidney from a patient with recurrent IgAN, we
demonstrated a 120-fold accumulation of SIgA compared to
IgA1 in the eluate. In conclusion, we have demonstrated that
SIgA strongly binds to human mesangial cells, and is present
in significant amounts in serum. Furthermore, we showed
that SIgA is accumulated in the glomeruli of an IgAN patient.
These data suggest an important role for SIgA in the
pathogenesis of IgAN.
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Primary IgA nephropathy (IgAN) is the most common form
of primary glomerulonephritis. The disease shows a spectrum
of clinical presentations, leading to progressive renal failure
in a substantial proportion of patients. The hallmark of this
disease is deposition of IgA in the glomerular mesangium.1–3
It is generally thought that deposits of IgA mainly involve
IgA1 and, for a large part, consist of high molecular weight
(HMW) IgA.4 The composition of HMW forms of IgA in the
serum is diverse and may include dimeric IgA, CD89/IgA
complexes, IgA immune complexes and IgA–fibronectin
complexes.5–9
Several reports have shown that the glycosylation of IgA1
in patients is different from that in controls. Patient IgA1
contains more terminal GalNAc, and this could play a role in
the deposition of IgA1 in the mesangium.10–12 IgA from the
glomeruli of IgAN patients consists at least partly of HMW
IgA13 and is under-O-glycosylated.10,14 In these studies, no
data was presented concerning the presence of secretory IgA
(SIgA). When deposited in the kidney, the IgA1-containing
complexes are linked to inflammation. Stimulation of
mesangial cells with HMW IgA leads to enhanced production
of cytokines and chemokines, including interleukin (IL)-6,
transforming growth factor-b, tumor necrosis factor-a,
monocyte chemoattractant protein-1, IL-8, and migration
inhibitory factor.15–18 These cytokines and chemokines might
play a role in the development and progression of renal injury
in IgAN patients.
SIgA is the dominant immunoglobulin in external
mucosal secretions like oral, respiratory and intestinal
cavities, and is often characterized as a component of the
immune systems’ ‘first-line defense’ against pathogenic
microorganisms.19 The SIgA molecule is composed of two
IgA monomers, linked by a junction peptide called J chain,
and the secretory component (SC) that wraps around the
dimer.20 Next to its presence in mucosal secretions, small
amounts of SIgA can also be found in human serum.21,22
Moreover, increased serum levels of SIgA have been reported
in various diseases,23–25 indicating that SIgA may be a marker
of clinical interest. A previous study has suggested that the
serum concentrations of SIgA are not different in IgAN
patients compared to healthy controls.23 The physiological
roles of serum IgA and SIgA are quite different, and the
presence of the highly glycosylated SC can have major effects
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on the biological functions of SIgA.26,27 In the literature, it is
still controversial if SIgA is able to bind to mesangial
cells.28,29 One study showed that SIgA is able to bind to
mesangial cells;28 however, this could not be confirmed in
another study.29
In the present study, we investigated the presence of SIgA
in the sera of IgAN patients and healthy controls, and
examined the binding of different molecular forms of IgA to
human mesangial cells with special interest for SIgA. Finally,
we investigated the presence of SIgA in the glomerular eluate
of an IgAN patient.
RESULTS
Specific detection of SIgA in human serum
An enzyme-linked immunosorbent assay (ELISA) system was
developed to specifically measure the amounts of SIgA in the
serum. In this system, anti-SC antibodies (Abs) were coated,
samples were applied and SIgA was detected with anti-IgA
Abs. Purified SIgA was readily detected by this ELISA with a
detection limit of 100 ng/ml (Figure 1a). In contrast, purified
monomeric serum IgA is not recognized in the ELISA, even
when applied at high concentrations (Figure 1a). In
accordance with previous publications,23 a specific signal
for SIgA could be detected in the serum of healthy
individuals (Figure 1b). The specificity of this assay is
especially dependent on the specificity of the anti-SC Ab.
Using Western blot, we showed that this monoclonal Ab only
recognized the 75 kDa SC (Figure 2a). Furthermore, compari-
son of the NI194-4 Ab with another anti-SC Ab 3F830 showed
specificity for SIgA, both in a direct ELISA (Figure 2b) and in
a sandwich ELISA (Figure 2c).
To determine the molecular size of SIgA in the serum, IgA
was isolated from the serum using affinity chromatography.
Size fractionation revealed that SIgA was specifically present
in the HMW fractions (Figure 3a). Using the same procedure,
IgA was isolated from eight healthy controls followed by gel
filtration. Pools containing polymeric serum IgA (pIgA) and
monomeric serum IgA (mIgA) were obtained and assessed
for the amount of SIgA (Figure 3b). In all cases, SIgA was
demonstrated exclusively in the pIgA pool.
Next, we assessed concentrations of SIgA in the serum of
47 IgAN patients and 19 healthy controls (Figure 4a). Both in
controls and in patients, significant serum concentrations of
SIgA were detected. There was no significant difference
(P¼ 0.159) in the SIgA concentrations in the serum of
patients (3.373.0 mg/ml) compared to that of controls
(2.271.2 mg/ml). After comparison of the SIgA concentration
in the serum of IgAN patients with different clinical
parameters, there were no correlations found. However,
concentrations of SIgA in IgAN patients were more
heterogeneous than in controls. Therefore, we divided the
IgAN group into patients with elevated levels of SIgA
(X5 mg/ml, mean72 s.d. of control sera) and patients with
normal levels (o5 mg/ml). There were no significant correla-
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Figure 2 | Specific detection of SIgA and secretory component.
(a) Detection of secretory component in SIgA, 1 and 0.2 mg SIgA were
loaded on 10% SDS-PAGE gel under reducing conditions after
blotting secretory component was detected with 2 mg/ml NI194-4.
(b) Detection of secretory component with NI194-4 and 3F8 (2 mg/ml)
in different molecular forms of IgA (2 mg/ml) coated on 96- well Nunc
maxisorp microtiter plate. (c) Different forms of IgA measured with
sandwich ELISA using two different coating antibodies (NI194-4 and
3F8).
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Figure 1 | Specific detection of SIgA in human serum. (a) Purified
SIgA and monomeric serum IgA were measured in a sandwich ELISA,
as detailed in the Materials and Methods. (b) Measurement of SIgA in
serum from healthy individuals in different serum dilutions. NHS,
normal human serum.
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Figure 3 | SIgA is present in high molecular weight fractions of
serum IgA. (a) IgA was affinity purified and size fractionated on a
HiLoadTM 16/60 HR200 Superdex prep grade gelfiltration column. All
fractions were measured for total protein and the presence of total
IgA and SIgA by ELISA. (b) From eight healthy controls, IgA was
purified and size fractionated as above. IgA was pooled in pIgA
fraction (39–47.5 ml) and mIgA fraction (47.5–57 ml). Both IgA and
SIgA concentrations were determined, and depicted is the amount of
SIgA corrected for the amount of total IgA. The horizontal dashed line
represents the detection limit. The horizontal solid lines indicate the
median.
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tions between the degree of proteinuria or creatinine
clearance and the serum concentration of SIgA (Figure 4b).
However, there was significantly more pronounced hematuria
in the group with higher levels of SIgA (P¼ 0.04) (Figure 4b).
SIgA binds to mesangial cells and induces cell activation
After demonstrating the presence of SIgA in the circulation, we
investigated its capacity to interact with mesangial cells. After
incubation of the mesangial cell line adult mesangial cells
(AMC)11 or normal human mesangial cells (NHMC) with
200mg/ml of different molecular forms of IgA, the binding was
examined by fluorescence-activated cell sorting (FACS)
analysis. Binding of mIgA to NHMC is very low (Figure 5a).
In contrast, the polymeric form of serum IgA showed a clear
binding to mesangial cells. However, the best binding was
observed with similar concentrations of SIgA, which occurred
in a dose-dependent manner, present over a wide range of
concentrations (Figure 5b). Although the mean fluorescence
intensity of IgA binding to NHMC, compared with AMC11,
was overall higher for all forms of IgA, the relative differences
between the different forms of IgA were the same.
The different molecular forms of IgA were compared for
their capacity to induce IL-6 production by mesangial cells.
Stimulation of NHMC for 72 h with IgA resulted in an
increased IL-6 production. This increase was most prominent
following stimulation with SIgA (Figure 6a). The induction
of IL-6 production by mesangial cells was dose dependent: a
17-fold increase was observed compared to the negative
control upon stimulation with 200 mg/ml SIgA (Figure 6b).
Mesangial cells do not express the mannose receptor (CD206)
or MAC-1 (CD11b/CD18)
Recently, we showed that dendritic cells (DCs) are able to
bind SIgA via the mannose receptor (CD206).31 Therefore,
we investigated the presence of the mannose receptor as a
potential SIgA receptor on mesangium cells. However, using
both FACS analysis (Figure 7a) and reverse transcriptase-
polymerase chain reaction (RT-PCR) (Figure 7b), we were
not able to demonstrate the presence of the mannose receptor
on mesangial cells. In both cases, DCs served as a positive
control. Similarly, we were not able to demonstrate the
presence of CD11b/CD18 (Figure 7c), recently identified as a
coreceptor for SIgA binding.32
Binding of SIgA to mesangial cells is not inhibited by SC,
EDTA and calcium
To investigate in more detail the mechanism of binding of
SIgA to mesangial cells, the cells were preincubated with free
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Figure 4 | Measurement of SIgA in the serum of IgAN patients
and controls and relation to clinical parameters. (a) The
concentrations of SIgA were determined in serum from patients
(n¼ 47) and controls (n¼ 19). The horizontal dashed line represents
the detection limit and the horizontal solid lines indicate the median.
(b) Based on SIgA concentrations, IgAN patients were divided in two
groups: normal SIgA levels (o5 mg/ml; meanþ 2 s.d. of control sera)
and increased SIgA levels (X5 mg/ml). These groups were analyzed
for proteinuria, creatinine clearance (700*: 700 multiply with
creatinine in urine (mmol/24 h)/creatinine in serum (mmol/l)) and
erythrocyturia at the time of sampling. The horizontal solid lines
indicate the median. Statistics were performed using the
Mann–Whitney test (NS¼ not significant).
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Figure 5 | Binding of SIgA to mesangial cells. (a) Normal human
mesangial cells (NHMC) were incubated with different molecular
forms of IgA (200 mg/ml) and assessed for IgA binding by flow
cytometry. Filled histograms represent the binding of IgA and the
open histograms represent the control staining with secondary
antibodies. (b) FACS analysis with AMC11 was performed using
increasing doses of SIgA (Sigma) and pIgA (isolated from a healthy
individual). Depicted is the mean fluorescence intensity (MFI).
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Figure 6 | SIgA increase IL-6 production by mesangial cells.
(a) Normal human mesangial cells (NHMC) (25 103 cells/well) were
stimulated with different molecular forms of IgA (200 mg/ml). After
72 h, supernatants were harvested and tested for IL-6 using ELISA.
Depicted is the mean7s.d. (b) NHMC was stimulated with different
concentrations of SIgA (Sigma) as described above and IL-6
production was assessed.
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SC. After preincubation with SC, the binding of SIgA to
mesangial cells was not affected (Figure 8a). Binding of SIgA
was slightly inhibited with SIgA and pIgA but not with mIgA
(Figure 8a), suggesting interaction with the IgA part of the
molecule.
To investigate the potential contribution of C-type lectins,
a family of cell surface molecules including the mannose
receptor, the role of calcium in SIgA binding to human
mesangial cells was examined. However, neither the addi-
tion of extra calcium nor the removal of calcium using
ethylenediaminetetraacetic acid (EDTA) showed a signi-
ficant effect on the binding of SIgA to mesangial cells
(Figure 8b).
SIgA is present in the glomerular eluate from a kidney of an
IgAN patient
To determine the potential role of SIgA in the pathogenesis of
IgAN, we had the unique opportunity to analyze the
glomerular eluate of a nephrectomized specimen derived
from a patient with recurrent IgAN. After elution, concen-
trations of specific immunoglobulin isotypes were deter-
mined. In the glomerular eluate, all immunoglobulin classes
measured were detectable (Table 1), including SIgA in a
concentration of 2 mg/ml. To exclude that the immuno-
globulins in the eluate were the result of aspecific trapping
from the circulation, serum immunoglobulin levels were
determined in the serum of this patient at the time of
nephrectomy (Table 1). The ratio of the immunoglobulin
concentrations in the eluate and the serum can be used as a
measure of the specific accumulation in the glomerular
deposit (Figure 9). In this analysis, we observed a ratio for
SIgA, which was 120-fold higher that the ratio for IgA1.
DISCUSSION
This is the first study to support a role for SIgA in the
pathogenesis of IgAN. We show that SIgA is present in low
concentrations in the serum of healthy individuals as well as
in IgAN patients. In patients with higher SIgA serum
concentrations, hematuria is more pronounced. Further-
more, we show that SIgA exhibits the strongest binding to
mesangial cells than serum IgA. Finally, in the eluate of
glomeruli from a kidney of an IgAN patient, a strong
accumulation of SIgA was detected. Taken together, these
data suggest an important role for SIgA in the pathogenesis
of IgAN.
The high incidence of IgAN recurrence after renal
transplantation, and the disappearance of deposits of IgA
from accidentally transplanted kidneys clearly suggests that
intrinsic alterations and/or structural characteristics of IgA
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Figure 7 | Mannose receptor and MAC-1 are not present on
mesangial cells. (a) FACS analysis of mannose receptor on DC and
AMC11. Filled histograms represent expression of mannose receptor;
open histograms represent the control staining with secondary
antibodies. (b) Mannose receptor mRNA expression was analyzed by
RT-PCR as described in the Materials and Methods (c) Presence of
MAC-1 on mesangial cells and DC was tested with FACS analysis.
Filled histograms represent expression of MAC-1. Open histograms
represent the control staining with secondary antibodies.
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Figure 8 | Binding of SIgA to mesangial cells is not affected by
free secretory component or calcium but is affected by IgA.
(a) Mesangial cells were preincubated with mIgA, pIgA, SIgA
(400mg/ml) or free secretory component (SC) (100mg/ml). After 1 h,
SIgA (200 mg/ml) was added and the binding of SIgA to mesangial
cells was examined with flow cytometry. Depicted is the percentage
of SIgA binding of a representative experiment of two experiments.
(b) Cells were incubated with SIgA (200 mg/ml) in the presence or
absence of EDTA (10 mM) or calcium (10 mM) followed by detection
of SIgA binding as described in the Materials and Methods.
Table 1 | Immunoglobulin concentrations in serum and
glomerular eluate of IgAN patient
IgA1 IgA2 SIgA IgM IgG
Serum (mg/ml) 5.9 0.59 0.016 0.74 10.0
Glomerular eluate (mg/ml) 6.1 0.65 2.0 2.2 6.8
IgA1 IgA2 SIgA IgM IgG
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Figure 9 | SIgA is accumulated in the glomerular eluate of an
IgAN kidney. To make an estimate for the specific accumulation in
the glomerular deposit, immunoglobulin concentrations in the eluate
and serum were compared. Depicted is the ratio of concentration of
different immunoglobulins in the eluate and the serum.
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contribute to the process of deposition.33,34 The predomi-
nance of IgA1 deposits and the specific hinge region of IgA1
with potential O-linked glycosylation sites have initiated a
directed search for alterations in glycosylation. Indeed, both
in the serum, but more importantly, in the eluate of renal
deposits,14 a specific reduction of O-linked galactosylation
has been observed.10,12,14,35 Furthermore, with size fraction-
ation of eluted proteins from kidney sections, it was shown
that deposited IgA was mostly HMW of nature.13 In addition,
based on different staining methods, it has been proposed
that a large part of the deposited IgA is of HMW of
nature.36–38
The results from all these methods provide indirect
indications for the composition of the IgA1 deposits. We
now show by eluting glomeruli that glomeruli display a
strong and specific accumulation of SIgA compared to other
serum immunoglobulins. However, this technique can only
be applied in limited cases of situations. We have tried to
demonstrate the presence of SIgA deposits using traditional
immunofluorescence on cryosections. Until now, we were not
able to show SIgA in renal sections, not even in cryosections
of the kidney used for our elution study. This might be due to
inappropriate reagents or conformational changes of the
deposited SIgA, thereby masking the SC epitope. Therefore, it
will be necessary to generate other reagents for the detection
of deposited SIgA and a more thorough analysis of renal
biopsies.
As described above, it is assumed that glycosylation of IgA
is an important factor in IgAN. Previous studies have shown
the role of the glycosylation of IgA on the activation of
mesangial cells,39,40 which could be partially explained by
altered interaction with mesangial cells.41 The glycosylation
of SIgA is different compared to that of serum IgA in several
aspects. First, SIgA is a tetramolecular complex consisting of
two IgA molecules, a J chain and the SC wrapped around the
H chain. Modelling of SIgA suggests that the N-glycans on
the heavy chain can be masked by the SC.42 This may also
result in a different exposure of the O-glycans. Moreover,
specific analysis of the glycosylation of the IgA heavy chain
present in SIgA demonstrated different N-glycan structures
compared to that of serum IgA, with terminal GlcNAc
residues on the majority of the N-glycans.42 The O-glycans
on the hinge region of the heavy chain of SIgA1 presented a
wide range of glycan structures, of which the major part is
now characterized.42 Finally, the SC itself is also heavily
glycosylated. However, we were not able to inhibit the
binding of SIgA to mesangial cells with SC, suggesting that
the SC part is not important for interaction with mesangial
cells. It will be a major challenge to isolate SIgA from the
serum of IgAN patients and to determine specific alterations
in glycosylation.
Having shown that SIgA strongly binds to mesangial cells,
an important question is which receptor is involved in this
binding and whether this receptor is different from that of
serum IgA. Several IgA receptors have been described in the
literature. The best-known receptors, the polymeric Ig
receptor (pIgR), the asialoglycoprotein receptor and CD89,
have already been described to be absent on mesangial
cells.28,43,44 The transferrin receptor is described as an IgA
receptor present on mesangial cells, but it has been reported
that this receptor is not able to bind SIgA.29 We have
previously reported the binding of SIgA to the mannose
receptor on DCs,31 but we were not able to demonstrate the
presence of the mannose receptor on mesangial cells.
Similarly, we were not able to demonstrate the presence of
CD11b/CD18 (MAC-1), a coreceptor for CD89 specifically
involved in recognizing SIgA or free SC.32 Therefore, until
now, we have no indication for the mesangial IgA receptor
involved in SIgA binding. Our inhibition experiments suggest
that IgA rather than SC is recognized and that no C-type
lectin is involved. Importantly, we found that the putative
receptor is able to transmit proinflammatory signals, since
SIgA induced a strong dose-dependent increase in IL-6
production by mesangial cells. This seems in contrast with
the proposed anti-inflammatory role of SIgA.45
Generation of SIgA, that is, production of dimeric IgA
(dIgA) followed by transcytosis using the pIgR, is a specific
process taking place at mucosal surfaces.46 Interestingly,
IgAN patients often present macroscopic hematuria follow-
ing upper respiratory tract infections. Mucosal challenge also
leads to an increased production of IgA in the systemic
compartment, probably based on the migration of B cells (the
mucosa–bone marrow axis).47 This mucosa–bone marrow
traffic has been confirmed by challenging healthy individuals
intranasally with the neoantigen cholera toxin subunit B
(CTB).48 In patients with IgAN, we observed a reduced
mucosal IgA response to mucosal immunization with CTB.48
At present, it is not clear whether a mucosal challenge also
regulates levels of circulating SIgA. Still, our finding of
glomerular accumulation of SIgA provides a link between the
mucosal immune system and renal deposits.
In summary, we have shown that SIgA is able to bind to
mesangial cells in a dose-dependent manner and that this
binding is calcium independent and cannot be inhibited with
free SC. Furthermore, low concentrations of SIgA can be
detected in serum. Further research is needed to determine to
which receptor SIgA can bind to and what the mechanism of
cell activation induced by SIgA. SIgA is strongly accumulated
in the glomeruli of a kidney from an IgAN patient. Therefore,
we conclude that our data support a role for SIgA in the
pathogenesis of IgAN, and further research to define such a
pathogenic role is warranted.
MATERIALS AND METHODS
Human subjects
In this study, we included 19 healthy volunteers and 47 patients with
primary IgAN.49 The latter were defined by mesangial deposits of
IgA. None of these patients had clinical or laboratory evidence of
Henoch Schoenlein purpura, systemic lupus erythematosus, liver
disease, or received immunosuppressive therapy. Patients were
included in the study between October 1998 and February 1999.
Blood and urine samples were collected, clinical characteristics and
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laboratory data of the patient group were obtained (Table 2)
retrospectively (observation time 5.970.5 years) and prospectively
(follow-up time 3.770.2 years).
Renal cortex was obtained from a transplant nephrectomy from a
male patient (1977), with biopsy-proven recurrent IgAN. He was
diagnosed with macroscopic hematuria (serum creatinine 146 mmol/
l) in 1993. The renal biopsy of 1996 showed characteristic features of
progressive IgAN, and dialysis was started. In April 2002, he received
a cadaveric renal transplantation. Three months later, a decline in
renal function was observed and a renal biopsy showed the presence
of interstitial nephritis and recurrent IgAN. In a biopsy taken 6
months following transplantation, characteristics of the interstitial
nephritis disappeared, but IgA was still present. Owing to decreased
patient compliance, there were two episodes of acute rejection in
2003 and 2004, which eventually led to graft loss. Informed consent
was obtained from all subjects.
IgA purification
Serum from healthy controls was used for IgA purification,
according to methods described earlier.9 In brief, serum was applied
to an anti-IgA (HisA 43, kindly provided by Dr J van den Born, Free
University Medical Center, Amsterdam) affinity column. IgA was
eluted with 0.1 M glycine/0.3 M NaCl (pH 2.8). The eluted protein
fractions containing IgA, as assessed by ELISA,50 were pooled and
dialyzed. The IgA was size separated with a HiLoadTM 16/60 HR200
Superdex prep grade gelfiltration column (120 ml; Amersham
Pharmacia, Roosendaal, The Netherlands) into pIgA and mIgA.
Cell culture
NHMC (Cambrex, NJ, USA) were expanded according to the
protocol provided by the manufacturer. Experiments with NHMC
were performed in RPMI with 10% fetal calf serum (FCS), 1%
nonessential amino acids, 0.5% transferrin/insulin/selenium, 1%
sodium pyruvate, and 1% L-glutamine (all purchased at Gibco/life
Technologies, Paisley, Scotland). AMC11, a spontaneously growing
adult human mesangial cell line (kindly provided by Professor
Holthofer, Helsinki, Poland), was cultured in Dulbecco’s modified
Eagle’s medium with 10% FCS. Cells were cultured in culture flasks
(Greiner, Frickenhausen, Germany) at 371C in a humidified
incubator with 5% CO2/95% air. For passage, the cells were
harvested by trypsinization (0.02% (w/v) EDTA/0.05% (w/v)
trypsin in phosphate-buffered saline (PBS) from Sigma (St Louis,
MO, USA)).
Monocyte-derived DCs were generated as described earlier.51
Flow cytometry
Cells were harvested, washed with FACS buffer (0.5 PBS contain-
ing 1% bovine serum albumin (BSA)/2.8% glucose/0.01% NaN3)
and incubated with mIgA and pIgA, and SIgA (Sigma). Following
incubation for 1 h at 41C, cells were washed and incubated for 1 h at
41C with monoclonal anti-IgA Ab 4E8 (IgG1).50 IgA binding was
visualized using phycoerythrin (PE)-conjugated goat anti-mouse
IgG1 (Southern Biotechnology, Birmingham, AL, USA) and assessed
for fluorescence intensity by flow cytometry (FACSCalibur, Cell
quest software; BD Biosciences, San Jose, CA, USA). Dead cells,
identified by propidium iodide uptake, were excluded from analysis.
For analyzing the presence of the mannose receptor, anti-
mannose receptor Ab (D547.3; kindly provided by F Koning, Leiden
University Medical Center, Leiden, The Netherlands) was used
followed by PE-conjugated goat anti-mouse Ig (Dako, Glostrup,
Denmark). For the detection of the two chains of MAC-1, anti-
human CD11b (leu-15-PE; BD Biosciences) and anti-CD18 (IB4;
ATCC, Manassas, VA, USA) were used.
For inhibition of the binding of SIgA to mesangial cells, the cells
were preincubated with purified free SC (100 mg/ml),52 10 mM EDTA
or 10 mM CaCl2 for 1 h at 41C. Subsequently, without washing, SIgA
was added and this binding was visualized as described above.
Inhibition of binding of SIgA was also detected with a preincubation
of IgA for 1 h at 41C, and subsequently, Alexa-conjugated SIgA was
added. After 1 h, the binding of Alexa-conjugated SIgA was
measured.
Cytokine analysis
Production of IL-6 was measured in supernatants of mesangial cells
after 72 h stimulation. Prior to stimulation, cells were transferred to
48-well plates (Costar, Corning, NY, USA) at a density of 25 103
cells/well and cultured overnight in culture medium with 0.5%
serum. Cells were stimulated with IL-1a, serum IgA, or SIgA. The
concentration of IL-6 in culture supernatants was measured by
specific ELISA as described previously.53
RNA extraction and RT-PCR
Total RNA was extracted from mesangial cells using RNeasy mini kit
(Qiagen, Valencia, CA, USA). Optical density (OD)260/280 ratio was
measured to determine the quantity and purity of RNA prepara-
tions. Fixed amounts of total cellular RNA (1mg) were reverse
transcribed into cDNA by oligo(dT) priming, using Moloney-
murine leukemia virus reverse transcriptase (Gibco/Life Techno-
logies, Breda, The Netherlands). PCR to detect the human mannose
receptor was performed with specific primers (sense 50-TTG AGT
GGA GTG ATG GGA CC-30; antisense 50-TTT CTG GAC CTT GGC
TTC GT-30) using AmpliTaq DNA polymerase (Applied Biosystems,
Roche, Mannheim, Germany). The PCR reaction was performed
under standard conditions.54 The cDNA samples were also subjected
to PCR for glyceraldehyde-3-phosphate dehydrogenase as an
internal control54 PCR products were resolved on 1% agarose gels
and bands were visualized by ethidium bromide staining.
Preparation of glomerular eluate
Glomeruli were isolated from a nephrectomized kidney from a
transplanted IgAN patient with recurrent disease. For this purpose,
the renal cortex was separated from the medulla. After slicing the
cortex into little pieces, the glomeruli were collected on a 150-mesh
sieve and stored at 701C with protease inhibitors (Complete, Mini,
Roche). The glomeruli were washed with PBS and the final pellet
was resuspended in 5 ml of elution buffer (2 M potassium
thiocyanate in 0.01 M phosphate buffer, pH 7.6) as described
earlier.55 After stirring at room temperature (RT) for 60 min, the
Table 2 | Clinical characteristics of the patients with IgAN at
the point of serum SIgA measurement
Number
of patients Median Range
Male/female 38/9
ACE-inhibitor/AII antagonist 24/3
Age (years) 47 19–69
Systolic blood pressure (mmHg) 130 100–160
Diastolic blood pressure (mmHg) 80 55–100
Proteinuria (g/day) 0.6 0.1–5.2
Glomerular filtration rate (ml/min) 71 15–137
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suspension was centrifuged at 8000 g for 15 min at 41C in a high-
speed centrifuge (Beckman, Avanti J25-1). The supernatant was
collected and dialyzed overnight against PBS. The precipitate that
was formed during dialysis was removed by centrifugation for
15 min at 17 000 g and was negative for immunoglobulins. The
remaining supernatant was concentrated to one-third of the original
volume.
ELISA for human SIgA, IgA1, IgA2, IgG and IgM
To test the specificity of the Abs used for the SIgA ELISA, 96-well
Nunc Maxisorb microtiter plate (Gibco/Invitrogen, Carlsbad, CA,
USA) was coated with 2 mg/ml IgA and BSA in carbonate buffer (pH
9.6) overnight at RT. After washing, the plate was incubated with
monoclonal Abs (2 mg/ml) specific for SC: NI194-4 (IgG1-k; Nordic
Immunology, Tilburg, The Netherlands)56 or 3F8 (kindly provided
by Dr RM Goldblum, University of Texas Medical Branch,
Galveston, TX, USA)30 in PBS/1% BSA/0.05% Tween for 1 h at
371C. Bound Ab was detected with goat anti-mouse Ig horseradish
peroxidase (HRP) (Dako). Enzyme activity of HRP was developed
using 2,20-azino-di(3-thylbenstialozone (ABTS) (Sigma). The OD at
415 nm was measured using a microplate biokinetics reader
(EL312e, Biotek Instruments, Winooski, Vermont, CA, USA).
In order to quantify SIgA levels in isolated IgA and serum, a
sandwich ELISA specific for SIgA was developed. Plates were coated
with 2 mg/ml monoclonal Ab specific for SC (NI194-4; 3F8) in
carbonate buffer (pH 9.6) (100 ml/well) overnight at RT. Subse-
quently, the plates were washed with PBS/0.05% Tween. Plates were
incubated with IgA or with serum from patients and controls in
PBS/1% BSA/0.05% Tween for 1 h at 371C. After washing, bound
IgA was detected using mouse anti-human IgA (4E8) conjugated to
digoxigenin (Dig), followed by F(Ab)2 anti-Dig Abs conjugated to
HRP (Roche). Enzyme activity of HRP was developed using ABTS
(Sigma). The OD at 415 nm was measured. A calibration line was
produced using purified SIgA (Sigma).
Concentrations of IgA1, IgA2, IgG, and IgM in sera and
glomerular eluate were determined using specific ELISAs.57
Western blot analysis
IgA preparations were subjected to 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing
conditions, followed by semidry blotting to polyvinylidine difluoride
(immobilin-P, Millipore, Bedford, MA, USA). Blots were blocked for
2 h at RT in TBS/0.1% Tween/5% skim milk powder (Fluka, Buchs,
Switzerland). Blots were subsequently incubated with 2 mg/ml
monoclonal Ab specific for SC (NI194-4) in TBS/0.1% Tween/
2.5% skim milk powder overnight at 41C. After washing with TBS/
0.1% Tween, blots were incubated with HRP-conjugated goat anti-
mouse immunoglobulin (Dako) for 2 h at RT. After washing, bands
were visualized with Supersignal (Pierce Chemical Co., Rockford, IL,
USA) and exposure to HyperfilmTM films (Amersham Pharmacia).
Statistical analysis
Statistical analysis was performed using the Mann–Whitney test.
Differences were considered statistically significant when P-values
are less than 0.05.
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